What Is Tesamorelin?

Tesamorelin consists of all 44 amino acids of human GHRH with an added trans-3-hexenoic acid group at the N-terminus. This structural modification enhances the peptide's stability and resistance to enzymatic degradation compared to native GHRH, resulting in a longer duration of action and improved pharmacokinetic profile.

Theratechnologies, the Canadian pharmaceutical company that developed Tesamorelin, conducted multiple Phase III clinical trials demonstrating significant reductions in visceral abdominal fat — the metabolically dangerous deep fat surrounding internal organs. Unlike subcutaneous fat, visceral fat is strongly linked to cardiovascular disease, insulin resistance, and systemic inflammation, making its targeted reduction particularly valuable from a metabolic health perspective.

Tesamorelin activates the same endocrine pathway as natural GHRH, but with enhanced potency and duration:

• GHRH receptor agonism — Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs with high affinity, stimulating growth hormone synthesis and secretion.
• Pulsatile GH amplification — Like Sermorelin, Tesamorelin preserves the natural pulsatile pattern of GH release while significantly increasing pulse amplitude.
• IGF-1 elevation — Increased GH stimulates hepatic IGF-1 production, which mediates lipolytic and anabolic effects throughout the body.
• Targeted visceral lipolysis — Growth hormone preferentially mobilizes visceral fat through upregulation of hormone-sensitive lipase and beta-adrenergic receptor activity in visceral adipocytes.
• Preserved feedback regulation — The hypothalamic-pituitary axis remains functional, with somatostatin providing negative feedback to prevent GH excess.

Tesamorelin's benefits are supported by robust clinical trial data:

• Visceral fat reduction — Phase III trials demonstrated an average 15–18% reduction in visceral adipose tissue (measured by CT scan) over 26 weeks of treatment.
• Improved lipid profiles — Research shows reductions in triglycerides and improvements in cholesterol ratios associated with Tesamorelin use.
• Reduced liver fat — Studies demonstrate decreased hepatic fat fraction, suggesting potential benefits for non-alcoholic fatty liver disease (NAFLD) research.
• Cognitive benefits — A notable NIH-funded study found Tesamorelin improved executive function and verbal memory in older adults, likely mediated through IGF-1 signaling in the brain.
• Preserved lean mass — Unlike caloric restriction, Tesamorelin-induced fat loss occurs without significant loss of lean muscle tissue.

Tesamorelin is administered via daily subcutaneous injection:

• Standard dose — 2 mg subcutaneously once daily, injected into the abdomen. This is the FDA-approved dosing for lipodystrophy.
• Timing — Typically administered in the morning or evening, though some research protocols favor bedtime dosing to complement natural GH pulsatility.
• Treatment duration — Clinical trials used 26–52 week treatment periods. Visceral fat reduction begins within the first few weeks but continues to improve over months.
• Discontinuation note — Studies show visceral fat tends to reaccumulate after Tesamorelin discontinuation, suggesting ongoing administration may be needed to maintain benefits.

Tesamorelin should be reconstituted with sterile water (provided with pharmaceutical preparations) and stored refrigerated. Use within 14 days of reconstitution.

Tesamorelin's safety profile is well-documented through clinical trials and post-marketing surveillance:

• Injection site reactions — Erythema, pruritus, and pain at the injection site are the most common adverse events, reported in approximately 10% of subjects.
• Arthralgia — Joint pain occurs in a small percentage of subjects, consistent with elevated GH and IGF-1 levels.
• Peripheral edema — Mild fluid retention has been reported, typically resolving with continued use.
• Paresthesia — Tingling or numbness, usually transient, has been noted in clinical trials.
• Blood glucose effects — GH elevation can affect insulin sensitivity. Monitoring glucose levels is recommended in research protocols.

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy under the brand name Egrifta®. Use for any other purpose is off-label. This article is for informational purposes only and does not constitute medical advice. All peptides mentioned are sold for research purposes only.

Tesamorelin is available through both pharmaceutical and research peptide channels:

• Pharmaceutical grade — Egrifta® is available by prescription for HIV-associated lipodystrophy through specialty pharmacies.
• Research grade — For research applications, third-party tested peptide vendors offer Tesamorelin with COAs confirming identity and purity.

Ascension Peptides provides research-grade Tesamorelin at 99%+ purity with independent lab verification. Their batch-specific COAs, US-based shipping, and cold chain handling ensure you receive a product suitable for serious research. Fast 2–3 day delivery and knowledgeable customer support round out their offering.